These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 31105041)

  • 1. Chimeric antigen receptor-engineered regulatory T lymphocytes: promise for immunotherapy of autoimmune disease.
    Yi L; Weifan Y; Huan Y
    Cytotherapy; 2019 Sep; 21(9):925-934. PubMed ID: 31105041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
    Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
    Front Immunol; 2018; 9():2359. PubMed ID: 30369931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression.
    De Paula Pohl A; Schmidt A; Zhang AH; Maldonado T; Königs C; Scott DW
    Cell Immunol; 2020 Dec; 358():104222. PubMed ID: 33053469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.
    Terry LV; Oo YH
    Front Immunol; 2020; 11():565518. PubMed ID: 33072105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?
    Sadeqi Nezhad M; Seifalian A; Bagheri N; Yaghoubi S; Karimi MH; Adbollahpour-Alitappeh M
    Front Immunol; 2020; 11():603237. PubMed ID: 33324420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR Treg: A new approach in the treatment of autoimmune diseases.
    Beheshti SA; Shamsasenjan K; Ahmadi M; Abbasi B
    Int Immunopharmacol; 2022 Jan; 102():108409. PubMed ID: 34863655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Therapy With Regulatory T Cells: A Beneficial Alliance.
    Biswas M; Kumar SRP; Terhorst C; Herzog RW
    Front Immunol; 2018; 9():554. PubMed ID: 29616042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes.
    Tenspolde M; Zimmermann K; Weber LC; Hapke M; Lieber M; Dywicki J; Frenzel A; Hust M; Galla M; Buitrago-Molina LE; Manns MP; Jaeckel E; Hardtke-Wolenski M
    J Autoimmun; 2019 Sep; 103():102289. PubMed ID: 31176558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?
    Janssens I; Cools N
    Cell Immunol; 2020 Dec; 358():104236. PubMed ID: 33137651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing the inherent power of chimeric antigen receptor (CAR)-expressing regulatory T cells (CAR-Tregs) to treat autoimmune-related disorders.
    Kahmini FR; Shahgaldi S
    Mol Biol Rep; 2022 May; 49(5):4069-4078. PubMed ID: 35534581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases.
    Chen Y; Sun J; Liu H; Yin G; Xie Q
    J Immunol Res; 2019; 2019():5727516. PubMed ID: 32083141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
    Boroughs AC; Larson RC; Choi BD; Bouffard AA; Riley LS; Schiferle E; Kulkarni AS; Cetrulo CL; Ting D; Blazar BR; Demehri S; Maus MV
    JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30869654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
    Lin C; Zhang J
    Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology.
    Koristka S; Kegler A; Bergmann R; Arndt C; Feldmann A; Albert S; Cartellieri M; Ehninger A; Ehninger G; Middeke JM; Bornhäuser M; Schmitz M; Pietzsch J; Akgün K; Ziemssen T; Steinbach J; Bachmann MP
    J Autoimmun; 2018 Jun; 90():116-131. PubMed ID: 29503042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered antigen-specific regulatory T cells for autoimmune skin conditions.
    Mukhatayev Z; Ostapchuk YO; Fang D; Le Poole IC
    Autoimmun Rev; 2021 Mar; 20(3):102761. PubMed ID: 33476816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential.
    Haddadi MH; Hajizadeh-Saffar E; Khosravi-Maharlooei M; Basiri M; Negahdari B; Baharvand H
    Blood Rev; 2020 May; 41():100645. PubMed ID: 31813654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor.
    Radichev IA; Yoon J; Scott DW; Griffin K; Savinov AY
    Cell Immunol; 2020 Dec; 358():104224. PubMed ID: 33068914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology.
    Mohseni YR; Tung SL; Dudreuilh C; Lechler RI; Fruhwirth GO; Lombardi G
    Front Immunol; 2020; 11():1608. PubMed ID: 32793236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of regulatory T Cells in autoimmune orchitis.
    Jacobo P
    Andrologia; 2018 Dec; 50(11):e13092. PubMed ID: 30569653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T cell therapy: Current and future design perspectives.
    Rana J; Biswas M
    Cell Immunol; 2020 Oct; 356():104193. PubMed ID: 32823038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.